Mitchell McLeod Pugh & Williams’s Grace Therapeutics GRCE Stock Holding History

Mitchell McLeod Pugh & Williams’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-938	Closed	-$25K	–	226
2021 Q2	$25K	Hold	938	–	–	0.01%	220
2021 Q1	$27K	Hold	938	–	–	0.01%	212
2020 Q4	$15K	Hold	938	–	–	0.01%	204
2020 Q3	$9K	Hold	938	–	–	﹤0.01%	198
2020 Q2	$21K	Hold	938	–	–	0.01%	186
2020 Q1	$17K	Hold	938	–	–	0.01%	166
2019 Q4	$110K	Sell	938 -104	-10%	-$10.3K	0.07%	173
2019 Q3	$95K	Buy	+1,042	New	+$96.5K	0.06%	173

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Mitchell McLeod Pugh & Williams's GRCE Position: Q3 2021 in Review

Mitchell McLeod Pugh & Williams sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 938 shares — an estimated $25K sold.

Mitchell McLeod Pugh & Williams first reported a position in GRCE in Q3 2019 and held it in 8 quarters. The position peaked at $110K in Q4 2019. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

Mitchell McLeod Pugh & Williams reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
Mitchell McLeod Pugh & Williams sold 938 Grace Therapeutics shares in Q3 2021, an estimated $25K.
Mitchell McLeod Pugh & Williams first reported a position in Grace Therapeutics in Q3 2019 and held it in 8 quarters.
Mitchell McLeod Pugh & Williams's Grace Therapeutics position peaked at $110K in Q4 2019.
17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Mitchell McLeod Pugh & Williams's 13F filing for Q3 2021, filed 8 Nov 2021.